Coronavirus Vaccine in Taiwan - April 2021

On another workday in Taiwan, there were 1752 vaccine doses administered—first doses only, with the second doses on the distant horizon.

Let’s roughly estimate Taiwan’s population to be 23,000,000. If they keep up this daily pace, it’ll take almost 36 years to administer the first dose to everyone. :slightly_frowning_face:



No need to hurry up a lot if there is by far not enough vaccine

1 Like

Maybe they are waiting for the vaccine that’ll cover COVID-25 to COVID-35.
Always invest long-term.


The first of the COVAX-distributed vaccines—199,200 more doses of AstraZeneca—are apparently scheduled to arrive tomorrow from Amsterdam:



[afterspivak] The first of the COVAX-distributed vaccines—199,200 more doses of AstraZeneca—are apparently scheduled to arrive tomorrow from Amsterdam:

Lots of European countries only give AstraZeneca to older people because of the blood clotting issue with AstraZeneca which is largely a problem of younger people (<50 or 60) and particularly females. And in those countries in Europe where there is no age limit, this is justified with the risk of dying from covid being higher than the risk of dying from the potential blood clots. But in Taiwan there is virtually no covid risk. So this is really something the Taiwanese government needs to think about long and hard.


Have you seen the stats for the serious (i.e. something like 40% fatal) blood clotting?


Nobody is talking about 40% dying from blood clotting. But as far as I know 40% of the population in Taiwan has also not died from covid or is at imminent risk of doing so. Your rhetorical question is therefore really rather misleading

And just for the record: I am for vaccination in principle. But nevertheless the specifics of the Taiwanese situation really lead to the question I posed concerning AstraZeneca

Canadian authorities—who recently paused the use of the AZ vaccine on people under 55—cited the 40% stat. This of course is NOT indicating that 40% of people get these serious blood clots; it’s indicating that among the people who did get the serious blood clotting, around 40% die, which is obviously not good.

What I am asking you is if you are aware of the percentage of people who have received the AZ vaccine who have then been afflicted by these serious blood clots. It’s a genuine question for you.


Apologies, I misunderstood your question.

From a recent newspaper article:

In Norway, health officials have reported at least six such cases among 120,000 recipients of the jab, four of whom died. In Germany, 31 cases have been reported after 2.7m vaccinations, including 29 women aged between 20 and 63, and two men aged 36 and 57. Nine of them have died.


So if I got this right, these very serious blood clot events have affected around 0.005% of AZ recipients in Norway, and around 0.001% of AZ recipients in Germany.

Additional data from Canada to follow.


From a CBC report from March 29:

Canada’s National Advisory Committee on Immunization (NACI) is recommending provinces pause the use of the AstraZeneca-Oxford COVID-19 vaccine on those under the age of 55 because of safety concerns — guidance most provinces said today that they would follow.

The change comes following reports out of Europe of very rare instances of blood clots in some immunized patients — notably among younger women.

But 300,000 of these shots have been administered in Canada already, with no reports of blood clots here, officials said. The blood clotting problem also has not been reported in people who have received mRNA vaccines like the Pfizer and Moderna products.

Speaking to reporters Monday, Dr. Shelley Deeks, the vice-chair of NACI, said that with “substantial uncertainty” around cases of vaccine-induced thrombocytopenia (VIPIT) in people with low platelets, the committee is recommending the suspension of shots in all people under 55 as a “precautionary measure.”

Based on early research out of Europe, VIPIT seems to be rare, occurring in anywhere from 1 in every 125,000 to 1 in 1 million people.

The European Union’s drug watchdog, the European Medicines Agency, has said it could not definitively rule out a link between the vaccine and rare types of blood clots associated with thrombocytopenia.

Specifically, it pointed to 18 cases of an extremely rare type of blood clot called cerebral venous sinus thrombosis (CVST), a condition that is much more common in women than men. Most of the cases occurred within 14 days of receiving the AstraZeneca shot, and the majority were in women under the age of 55.

Dr. Howard Njoo, Canada’s deputy chief public health officer, said people who develop stroke-like medical symptoms after receiving the AstraZeneca vaccine — shortness of breath, chest pain, leg swelling, abdominal pain, sudden onset of headaches or blurred vision — should immediately seek medical attention. There is no risk for people who have not developed such symptoms 20 days post-vaccination.

Source: Suspend AstraZeneca use for people under 55, vaccine committee recommends | CBC News


1 Like

Further info from the same article:

*Varied advice on the AstraZeneca vaccine *

*France and Canada are restricting the vaccine to people over 55 *
*Germany is recommending it only to people over 60 *
*Italy is restricting the jab to people under 80 *
*Austria and the UK have no restrictions in place Sweden and Finland are using it only for those over 65 *
In Norway and Denmark the shot is suspended until at least mid-April
Switzerland has still not approved the jab at all

1 Like

This was published a few weeks ago.

This most recently.

What worries me is whether with those numbers and not complete data, the decision is based more on political issues than scientific.


A “political decision” would be NOT to talk about these issues which appears to be kind of the UK approach. But in many of these European countries the laws are such that the governments would be legally liable if they did NOT mention this.

And since all these vaccines are new, we all have the unique opportunity to watch scientific progress in real time. That this is very confusing for large parts of the population is clear. But if the facts change, scientific recommendations change as well. And maybe it will be different again in a month and again different in two months. But that is the nature of the scientific process


The U.K. confirmed seven people had died from rare blood clots after receiving AstraZeneca Plc’s Covid-19 vaccine and Australia is also investigating a case of clotting, raising questions about the safety of the widely used coronavirus shot.

The U.K.’s Medicines and Healthcare Products Regulatory Agency said Saturday that of 30 cases of clotting and low blood platelets identified in people in the U.K. who had received the shot through March 24, seven had died. More than 18 million doses have been administered in the country and the regulator insists the shot is safe.

Australia said Saturday that it was cooperating with regulators in the U.K. and the European Union after identifying a case of blood clotting on April 2 in someone who had received the AstraZeneca shot.

The latest revelation will likely add to the growing concern over the AstraZeneca vaccine, which is the backbone of the U.K.’s successful inoculation campaign. Many countries around the world were relying on the AstraZeneca to drive their their immunization programs and now some are reconsidering despite growing levels of Covid cases.

The Netherlands Friday joined Germany in suspending the vaccine’s use in people under 60. Norway and Denmark extended suspensions on the use of the shot, which has also been the subject of a tussle over supplies between the EU, the U.K. and others.

South Africa Friday concluded the sale of 1 million of the shots to other countries after finding they had little impact on a variant first identified in the country last year.

The U.K. continues to forge ahead with its vaccine program, which has delivered a first shot to more than 60% of all adults. Prime Minister Boris Johnson has pledged to offer a first shot to all adults by the end of July, with the Astra vaccination critical to reaching that goal.

With the new reports of the clotting condition, the rate of incidents following the AstraZeneca shot in the U.K. is about 1 in 600,000. There were no reports of the same reactions to the vaccine from Pfizer Inc. and BioNTech SE, which is also being used in Britain.

Earlier this week, the EU drugs regulator said a link between the AstraZeneca vaccine and a rare type of blood clot is possible, identifying at least 62 cases of the condition. The European Medicines Agency said its safety committee will probably issue an updated recommendation next week.

1 Like

So after the European Medical Agency, the EU regulator, now also said that it has established a link between rare blood clots in the brain and the AstraZeneca jab and even the always optimistic UK government is recommending young people to get another vaccine instead of its own patriotic Astra Zeneca jab, it is time for the Taiwanese CDC to think about this given the minimal risk of infection in Taiwan.

1 Like

understatement of the century

They need a solid plan B yesterday

1 Like

Well, I am trying to be polite since I said the same thing earlier on and was kind of beaten up😉

You have to look at the statistics though, the chance of a clot with AZ is around 1 in 250,000.

The chance of a blood clot when taking the contraceptive pill is 1 in 2000.

Yet you don’t see mass panic from all the women taking their Yazz or Diane each month…


But if it can be avoided, if we can do something better, we should. Never settle.

1 Like